Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (6), 789-797
- https://doi.org/10.1016/j.annonc.2020.03.293
Abstract
No abstract availableFunding Information
- Novartis Pharmaceuticals Corporation
This publication has 31 references indexed in Scilit:
- MET As a Possible Target for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung CarcinomasJournal of Thoracic Oncology, 2012
- A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3Clinical Cancer Research, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor StatusJournal of Thoracic Oncology, 2010
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung CancersJournal of Thoracic Oncology, 2009
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung CancerCancer Research, 2006